Humanwell Healthcare (Group) Co. Ltd. has prepared and tested 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors reported to be useful for the treatment of fibrosis, tissue injury and inflammatory disorders.

Astrazeneca plc recently provided details on the discovery of the potent, direct and selective NLPR3 inflammasome inhibitor AZD-4144 for the treatment of inflammatory diseases.